HCM
AVXL icon

Highbridge Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Highbridge Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,968
Closed -$121K – 1236
2017
Q1 		$121K Sell
20,968
-17,131
-45% -$88.5K ﹤0.01% 1367
2016
Q4 		$151K Buy
+38,099
New +$136K ﹤0.01% 1170
2016
Q2 		– Sell
-50,704
Closed -$248K – 1383
2016
Q1 		$248K Buy
+50,704
New +$223K ﹤0.01% 1252

Other funds holding AVXL

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Highbridge Capital Management's AVXL Position: Q2 2017 in Review

Highbridge Capital Management sold out of Anavex Life Sciences (AVXL) in Q2 2017, closing a stake of 20,968 shares — an estimated $121K sold.

Highbridge Capital Management first reported a position in AVXL in Q1 2016 and held it in 3 quarters. The position peaked at $248K in Q1 2016. 61 funds tracked by Wall St. Rank hold AVXL as of Q2 2017.

  • Highbridge Capital Management reported no remaining Anavex Life Sciences position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 20,968 Anavex Life Sciences shares in Q2 2017, an estimated $121K.
  • Highbridge Capital Management first reported a position in Anavex Life Sciences in Q1 2016 and held it in 3 quarters.
  • Highbridge Capital Management's Anavex Life Sciences position peaked at $248K in Q1 2016.
  • 61 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.